Compare Natco Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AUROBINDO PHARMA NATCO PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 16.0 14.2 112.3% View Chart
P/BV x 3.1 3.1 101.5% View Chart
Dividend Yield % 1.4 0.4 350.5%  

Financials

 NATCO PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
NATCO PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,080809 133.5%   
Low Rs671504 133.2%   
Sales per share (Unadj.) Rs592.1281.1 210.7%  
Earnings per share (Unadj.) Rs188.441.4 455.6%  
Cash flow per share (Unadj.) Rs206.350.9 405.6%  
Dividends per share (Unadj.) Rs8.252.50 330.0%  
Dividend yield (eoy) %0.90.4 247.4%  
Book value per share (Unadj.) Rs833.6199.4 418.1%  
Shares outstanding (eoy) m36.90585.88 6.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.52.3 63.3%   
Avg P/E ratio x4.615.9 29.3%  
P/CF ratio (eoy) x4.212.9 32.9%  
Price / Book Value ratio x1.13.3 31.9%  
Dividend payout %4.46.0 72.4%   
Avg Mkt Cap Rs m32,311384,630 8.4%   
No. of employees `0004.817.3 27.9%   
Total wages/salary Rs m3,25621,308 15.3%   
Avg. sales/employee Rs Th4,522.59,500.7 47.6%   
Avg. wages/employee Rs Th674.01,229.4 54.8%   
Avg. net profit/employee Rs Th1,439.01,397.9 102.9%   
INCOME DATA
Net Sales Rs m21,848164,666 13.3%  
Other income Rs m4041,020 39.6%   
Total revenues Rs m22,252165,686 13.4%   
Gross profit Rs m9,28437,718 24.6%  
Depreciation Rs m6625,580 11.9%   
Interest Rs m154777 19.8%   
Profit before tax Rs m8,87232,380 27.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9208,183 23.5%   
Profit after tax Rs m6,95224,229 28.7%  
Gross profit margin %42.522.9 185.5%  
Effective tax rate %21.625.3 85.6%   
Net profit margin %31.814.7 216.3%  
BALANCE SHEET DATA
Current assets Rs m21,307121,878 17.5%   
Current liabilities Rs m5,92086,806 6.8%   
Net working cap to sales %70.421.3 330.7%  
Current ratio x3.61.4 256.3%  
Inventory Days Days73130 56.4%  
Debtors Days Days10768 155.8%  
Net fixed assets Rs m14,98681,037 18.5%   
Share capital Rs m369586 63.0%   
"Free" reserves Rs m30,353116,218 26.1%   
Net worth Rs m30,760116,804 26.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m37,151211,052 17.6%  
Interest coverage x58.642.7 137.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 75.4%   
Return on assets %19.111.8 161.4%  
Return on equity %22.620.7 109.0%  
Return on capital %29.327.4 107.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32280,727 12.8%   
Fx outflow Rs m2,97834,700 8.6%   
Net fx Rs m7,34346,027 16.0%   
CASH FLOW
From Operations Rs m4,63619,548 23.7%  
From Investments Rs m-11,155-19,570 57.0%  
From Financial Activity Rs m6,5098,642 75.3%  
Net Cashflow Rs m-188,922 -0.2%  

Share Holding

Indian Promoters % 52.0 54.1 96.2%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 8.0 98.6%  
FIIs % 16.6 27.7 60.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.2 254.9%  
Shareholders   25,395 69,601 36.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   ELDER PHARMA  FDC LTD.  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

GSK PHARMA Surges by 5%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 23, 2019 | Updated on Sep 23, 2019

GSK PHARMA share price has surged by 5% and its current market price is Rs 1,460. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 5.4%) and ABBOTT INDIA (up 6.3%). The top losers are ALKEM LABORATORIES (down 0.1%) and BIOCON (down 0.2%).

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 23, 2019 02:23 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS